Mathilde Leclercq- Université de Rouen Normandie
Mathilde Leclercq
- Université de Rouen Normandie
About
30
Publications
1,881
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
272
Citations
Introduction
Skills and Expertise
Current institution
Publications
Publications (30)
In up to 25% of patients with acquired TTP, anti-ADAMTS13 antibodies are not identified, the mechanism resulting from ADAMTS13 deficiency remains unidentified (uTTP). In this study, we provide further insights on clinical presentation and outcome of uTTP. In patients with baseline undetectable anti-ADAMTS13 antibodies, usual features of iTTP (young...
Aims
To compare the safety and efficacy of methotrexate (MTX), mycophenolate mofetil (MMF) and azathioprine (AZA) in non-anterior sarcoidosis-associated uveitis.
Methods
Retrospective study including non-anterior sarcoidosis-associated uveitis according to the revised International Workshop on Ocular Sarcoidosis criteria. The primary outcome was d...
Background
Neurosarcoidosis is a rare and severe manifestation, affecting between 3% and 15% of patients with sarcoidosis. The cornerstone of treatment is corticosteroid therapy. Several drug are available in the therapeutic arsenal: Cyclophosphamide (CYC), anti-TNFα biotherapy, conventional immunosuppressants, in particular Methotrexate (MTX). How...
Objectives:
To analyse in routine practice the efficacy of targeted therapies on joint involvement of patients with rheumatoid arthritis/systemic sclerosis (RA/SSc) overlap syndrome.
Methods:
This was a retrospective analysis of medical records of two academic centres over a 10-year period. Joint response to targeted therapies was measured accor...
Purpose
The efficacy of tocilizumab in refractory chronic noninfectious uveitis has been previously reported, but no data comparing intravenous and subcutaneous tocilizumab in uveitis are available.
Results
We report a case series of patients with chronic noninfectious uveitis with incomplete efficacy of subcutaneous tocilizumab, improved after sw...
Uveitis in Behçet’s disease (BD) is frequent (40% of cases) and is a major cause of morbidity. The age of onset of uveitis is between 20 and 30 years. Ocular involvement includes anterior, posterior, or panuveitis. Uveitis may be the first sign of the disease in 20% of cases or it may appear 2 or 3 years after the first symptoms. Panuveitis is the...
Objective:
To evaluate tocilizumab (TCZ) efficacy in refractory Behcet's Disease (BD) patients.
Methods:
Multicenter study of 30 patients fulfilling the International Criteria for BD and treated with TCZ at different European referral centres. The clinical response was evaluated at 6 months (M6) from TCZ initiation.
Results:
Ninety percent of...
Résumé
Contexte
Avec la réforme des études médicales, les examens cliniques objectifs et structurés (ECOS) deviennent un examen national. L’objectif de ce travail est d’identifier les facteurs, intrinsèques et extrinsèques à l’étudiant, associés à la réussite aux ECOS.
Méthodes
Un questionnaire nominatif a été distribué après l’épreuve d’ECOS (4...
Objective
To compare relapse rate of sight threatening non infectious uveitis (NIU) in patients treated with infliximab (IFX) or adalimumab (ADA).
Design
Observational retrospective multicenter study.
Subjects
330 patients (median age of 36 years (IQR 27-54), with 45.2% of men) with sight threatening NIU (i.e. retinal vasculitis and/or macular ed...
Introduction
Le syndrome de chevauchement polyarthrite rhumatoïde (PR)/sclérodermie systémique (ScS) est une association rare et peu étudiée. Elle concerne 5 % des patients atteints de ScS. Seules des études ouvertes ayant évalué les biomédicaments (bDMARDs) ont rapporté des résultats encourageants, notamment sur l’atteinte articulaire. La prise en...
Objective
To analyze the factors associated with response (control of ocular inflammation and corticosteroid sparing effect) to biologics (anti-TNF-α agents and tocilizumab) in patients with refractory uveitic macular edema.
Design
Multicenter retrospective observational study.
Subjects
Adult patients with uveitic macular edema refractory to syst...
Introduction: Non-infectious uveitis (NIU) is one of the leading causes of blindness worldwide. In adult patients, anterior NIU is usually managed with topical corticosteroids. In intermediate, posterior uveitis and panuveitis, systemic corticosteroids are used especially in case of bilaterality or association with systemic disease. Biotherapies ar...
Behçet’s disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the manag...
The term “vitritis” refers to the presence of a cellular infiltration of the vitreous body, usually in the context of an intraocular inflammation, but not exclusively. Intermediate uveitis is the most prominent cause of vitritis, including infectious and auto-immune/auto-inflammatory etiologies. Corticosteroids and immunosuppressive therapies shoul...
Background: Neuro-ophthalmologic manifestations are uncommon in sarcoidosis. We aim to assess the prognostic factors and outcome of neuro-ophthalmic sarcoidosis.
Methods: We conducted a multicenter retrospective study on patients with neuro-ophthalmic sarcoidosis. Response to therapy was based on visual acuity, visual field, and orbital MRI exam. F...
Non-infectious uveitis (NIU) represents one of the leading causes of blindness in developed
countries. The therapeutic strategy aims to rapidly control intra-ocular inflammation, prevent irremediable ocular damage, allow corticosteroid sparing and save the vision, and has evolved over the last few years. Anterior NIU is mostly managed with topical...
Objective
To compare the efficacy and safety of Disease-modifying antirheumatic drugs (DMARDs) and anti-TNF-α agents in patients with non-infectious non-anterior uveitis.
Methods
Single center retrospective study including adult patients with non-infectious intermediate, posterior or pan-uveitis. Outcomes were compared between patients treated wit...
Introduction
Les uvéites non-infectieuses non-antérieures représentent une cause majeure de cécité dans les pays industrialisés. Aujourd’hui, en cas de rechute sous corticothérapie ou de corticodépendance, l’intensification thérapeutique repose sur les immunosuppresseurs conventionnels (méthotrexate, mycophénolate mofétil ou azathioprine). Cependan...
Background
Orexins (hypocretins, Hcrt) A and B are GPCR-binding hypothalamic neuropeptides known to regulate sleep/wake states and feeding behavior. A few studies have shown that orexin A exhibits anti-inflammatory and neuroprotective properties, suggesting that it might provide therapeutic effects in inflammatory and neurodegenerative diseases lik...
Biotherapies appear as potential drugs for the treatment of inflammatory noninfectious uveitis. In this report, we show that tocilizumab, an anti-IL-6 agent, greatly improved two patients with birdshot chorioretinopathy refractory to conventional immunosuppressive drugs, interferon α2a, and anti-TNFα agents. After a follow-up of 22 months, patients...
